Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate

NCT03139136 is registered in ClinicalTrials.gov with Modern Biosciences Ltd as lead sponsor.

NCT NCT03139136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03139136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Lead sponsor
Modern Biosciences Ltd
Phase
Phase 2
Overall status
Completed
Start date
May 30, 2017
Completion date
August 13, 2019
Enrollment
121 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis